Evidence map›Paper›PMID 39194287›Full record

ArticleMicrobiology spectrum2024

Milteforan, a promising veterinary commercial product against feline sporotrichosis.

Laura C García Carnero, Camila Figueiredo Pinzan, Camila Diehl, Patricia Alves de Castro, Lais Pontes, Anderson Messias Rodrigues, Thaila F Dos Reis, Gustavo H Goldman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Osh2 mediatesAntimicrobial agents and chemotherapy · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Laura C García CarneroFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Camila Figueiredo PinzanFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Camila DiehlFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.ORCID 0000-0003-3174-0346
Patricia Alves de CastroFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Lais PontesFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Anderson Messias RodriguesDepartment of Microbiology, Immunology and Parasitology, Discipline of Cellular Biology, Laboratory of Emerging Fungal Pathogens, Federal University of São Paulo, São Paulo, Brazil.
Thaila F Dos ReisFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Gustavo H GoldmanFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.ORCID 0000-0002-2986-350X

Funding

Deciphering the phenotypic and genomic traits that underlie the evolution of pathogenicity differences among Aspergillus fumigatus and its close relativesR01AI153356 · NIAID · VANDERBILT UNIVERSITY · PI Antonis Rokas · 2022 to 2026
$3.5M
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2021/04977-5Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2022/08556-7Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2022/08796-8Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2022/09882-5NIAID NIH HHS R01 AI153356
6 · The paper itself

Abstract

Sporotrichosis, the cutaneous mycosis most commonly reported in Latin America, is caused by the IMPORTANCE: Sporotrichosis is an endemic disease in Latin America caused by different species of Sporothrix. This fungus can infect domestic animals, mainly cats and eventually dogs, as well as humans. Few drugs are available to treat this disease, such as itraconazole, terbinafine, and amphotericin B, but resistance to these agents has risen in the last few years. Alternative new therapeutic options to treat sporotrichosis are essential. Here, we propose milteforan, a commercial veterinary product against dog leishmaniasis, whose active principle is miltefosine, as a possible therapeutic alternative for treating sporotrichosis. Milteforan decreases

Indexed as

Antifungal AgentsCat DiseasesPhospholipidsSporotrichosisA549 CellsAnimalsCatsCell DeathCell MembraneCytokinesDogsMacrophagesMicrobial Sensitivity TestsMitochondriaPhosphorylcholineSporothrixAntifungal AgentsCytokinesmiltefosinePhospholipidsPhosphorylcholineantifungal agentdrug repurposingmilteforanmiltefosineSporothrix brasiliensisSporothrix schenckiisporotrichosis

Identifiers

PMID39194287
PMCPMC11448087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.